FEATURE ARTICLES
The market for GLP-1 agonists is booming and expected to only get bigger. As rates for obesity and cardiovascular disease increase, so too does the demand for GLP-1 drugs.
- From Lab to Plant: Managing Operational Environment During Scale-Up
- Sanofi's Digitalization Road Trip Shifts Into High Gear
- Why Pharmaceutical And Medical Device Risks Must Be Analyzed By Their Risk Mechanisms
- The Regulatory Imperative To Improve Environmental And Sustainability Stewardship In Biopharma
- Operating And Maintaining Pharmaceutical Gas Distribution Systems
- August 2025 — CDMO Opportunities And Threats Report
- The New FDA Era Of Radical Transparency And Pervasive Oversight
PHARMA ONLINE WHITE PAPERS
-
Understanding Biosafety Levels
Compliance with biosafety levels (BSLs) is crucial in ensuring that your laboratories meet stringent standards to protect staff and prevent the escape of biological agents.
-
Vial Breakage During Lyophilization: Root Causes And Mitigation10/16/2024
Learn how controlling freezing rates, using specialized vials, and employing optimized stoppering techniques can reduce the risk of vial breakage during lyophilization and ensure high product quality.
-
Normalized Data In Microbial Continuous Monitoring7/24/2025
Learn how EU GMP Annex 1 (2022) redefines cleanroom air monitoring standards and emphasizes continuous viable sampling in Grade A and B environments to ensure aseptic integrity and compliance.
-
Leveraging Life Sciences Data For Intelligent Decision-Making2/18/2025
Industry 4.0 drives life sciences to prioritize data-driven decision-making by integrating advanced technologies in QMS. Discover how modern data management can improve compliance.
-
Manufacturing Challenges With High Concentration Biologics3/18/2024
Explore key process operations, some of the challenges in manufacturing high-concentration biologics, and factors to consider for process optimization.
-
The Impact Of Annex 1 (2022) On Sterility Assurance4/24/2025
Airflow visualization studies, crucial for GMP compliance, validate unidirectional airflow effectiveness in contamination control. Discover their enhanced role in quality by design and revised Annex 1 guidelines.
PHARMA ONLINE APP NOTES & CASE STUDIES
- How A Top Biotech Achieved Right-First-Time Batches
- Aseptic Expertise And Delivery Of Services
- A Temperature-Stable Replacement For Animal Trypsin In Cell Dissociation Applications
- Difco TC Yeastolate Ultra-Filtered (TCY UF) In Scale-Up Optimization
- Overcoming The Solubility Challenges Of Antibody-Drug Conjugates
NEWSLETTER ARCHIVE
- 09.29.25 -- Application Of Process Analytical Technology In ADC Bioconjugation Processes
- 09.26.25 -- Lean Manufacturing Implementation In Pharmaceutical Injectable Facilities
- 09.25.25 -- Looking for more efficient process development?
- 09.25.25 -- Contamination Control Strategies For Drug Manufacturers
- 09.25.25 -- STREAM Edition: Considerations For Single Use Disposables
INDUSTRY NEWS
-
![GettyImages-2189405678-GLP-1-obesity]( "Pfizer Strengthens Obesity Foothold With Metsera Acquisition")
Pfizer Strengthens Obesity Foothold With Metsera AcquisitionAfter discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.
-
![weight loss, diabetes, insulin pen-GettyImages-2196049931]( "FDA Cracks Down On GLP-1 Imports")
FDA Cracks Down On GLP-1 ImportsGLP-1 bulk drug substances must be detained without physical examination (DWPE) unless they are on a list (Green List) of approved foreign GLP-1 manufacturers.
-
![Dollar Icon from Medical pills-GettyImages-1708867150]( "Oregon Court Upholds Drug Price Transparency Law")
Oregon Court Upholds Drug Price Transparency LawThe law was first enacted in 2018, followed by a lawsuit by Pharmaceutical Research and Manufacturers of America (PhRMA) in 2019, claiming an infringement of free speech for pharmaceutical companies and violation of public property. PhRMA asked the court to bar Oregon from enforcing the law.
-
![Healthcare-GettyImages-1287539899]( "Spray Drying Market Poised To Nearly Double By 2033")
Spray Drying Market Poised To Nearly Double By 2033The growth of the spray drying market is attributed to demand for enhanced stability, bioavailability and solubility of poorly soluble drugs.
-
![Psychedelic Drugs-GettyImages-157676497]( "AbbVie Enters Psychedelic Market With Bretisilocin Acquisition")
AbbVie Enters Psychedelic Market With Bretisilocin AcquisitionBretisilocin is a next-generation psychedelic compound (5-HT2A receptor agonist and 5-HT releaser) designed to exert a shorter duration of psychoactive experience, while retaining an extended therapeutic benefit
PHARMACEUTICAL ONLINE CONTENT COLLECTIONS
The modern microbiology laboratory is starting to look very different from the laboratory of even 10 years ago. The work will be similar, yet technology will have advanced. Automation, in particular, is taking center stage. Check out the latest e-book from Pharmaceutical Online.
More Content CollectionsSUPPLIER NEWS
-
Ritedose Scales Operations With $17M Laboratory Expansion9/25/2025
Ritedose is investing $17M to expand its cGMP labs, adding a 10,000 sq. ft. analytical chemistry facility and a 6,000 sq. ft. microbiology expansion to boost drug development and CDMO capabilities.
-
PolyPeptide Strengthens Global Peptide Production With Modular Facility Design Approach9/24/2025
PolyPeptide Group AG (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful delivery and installation of pre-built modules at its Malmö, Sweden facility. This marks a key milestone in the company’s modular expansion project at the site, which aims to double its solid-phase peptide synthesis (SPPS) capacity.
-
$60M Series B Financing Propels Avenzo Therapeutics Forward9/24/2025
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the closing of a $60 million Series B financing. This funding, which follows Avenzo’s $386 million Series A/A-1 financing announced in November 2024, brings the total capital raised to $446 million. The proceeds will be used to support the advancement of Avenzo’s pipeline of potential best-in-class oncology drug candidates.
-
Groninger Acquires Isolator And Cleanroom OEM Reinraumtechnik Ulm9/18/2025
With this strategic move, the family-owned company headquartered in Crailsheim not only expands its technological portfolio but also strengthens its expertise in a field that is crucial to the pharmaceutical industry: cleanroom and isolator technology.
-
GSK Commits $30B To U.S. R&D And Drug Manufacturing Expansion9/17/2025
GSK plc (LSE/NYSE: GSK) today announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.
